Archive for February, 2012

Ready, Fire, Aim: pharma’s diagnosis-free growth strategy

Ready, Fire, Aim: pharma’s diagnosis-free growth strategy

So the global pharma and biotech industry still has a pipeline problem: cost per new drug is sky rocketing, volume of new approvals continues to decline, and the influx of likely looking discovery assets is but a trickle. Meanwhile the industry continues to do what it has always done (i.e. implement new team re-structuring or budget allocation ideas), and get what it has always got.

Ready, Fire, Aim?

We still seem to know remarkably little about the drivers governing this pattern. The ...

Continue Reading →
0